2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4539 Daratumumab-lenalidomide maintenance after quadruplet induction and upfront autologous hematopoietic cell transplantation in multiple myeloma

Khalid G. G. Alharbi, MBBS, Denai Milton2, Mark R. Tanner, PhD, MBA, CMPP3, Qaiser Bashir, MD4, Samer A Srour, MB ChB, MS5, Neeraj Saini, MD6, Paul Lin, MD, PhD7, Jeremy Ramdial, MD8, Yago Nieto, MD, Ph.D9, Guilin Tang, MD, PhD,FACMG10, Yosra M. Aljawai, MD MS11, Krina Patel Jr, MD, MSc12, Jing Christine Ye, M.D., MSc13, Meera Mohan, MD, MS14, Sarvari V. Yellapragada, MD15, Cynthia B. Alas16, Rita Deeba, PA-C17, Yusuf F. Islam18, Mahmoud R. Gaballa, MD19, Partow Kebriaei, MD20, William Matsui, MD21, Sheeba Koshy Thomas, M.D.22, Robert Orlowski, MD, PhD23, Richard Champlin24, Elizabeth Shpall, MD25, Muzaffar Qazilbash, MD26, Oren Pasvolsky, MD27
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Randomized clinical trials, including GRIFFIN, PERSEUS and AURIGA, have demonstrated improved outcomes with daratumumab-containing frontline strategies and daratumumab plus lenalidomide (D-R) maintenance in transplant-eligible multiple myeloma. However, real-world data on D-R maintenance following D-VRd induction and upfront autologous hematopoietic stem cell transplantation (autoHCT) remain limited. We evaluated clinical outcomes with D-R maintenance in this setting.

Methods: We included patients with newly diagnosed MM treated at MD Anderson who received daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) induction, underwent upfront autoHCT between July 2022 and October 2025, and initiated D-R maintenance. Bone marrow MRD was measured by flow cytometry with a sensitivity of 10⁻⁵. High-risk MM was defined according to the 2025 International Myeloma Society/International Myeloma Working Group (IMS/IMWG) Consensus Genomic Staging criteria. Primary endpoints were progression free survival (PFS) and overall Survival (OS).

Results: Forty-three patients were included; the median age at autoHCT was 66 years (range, 40–78), 29 (67%) were male, and 12 (28%) self-identified as Black. Among 41 patients with known Revised-International Staging System staging, 9 (22%), 24 (59%), and 8 (20%) had stage I, II, and III disease, respectively. Twenty-two patients (51%) had high-risk disease.

The median duration of maintenance was 6.3 months (range, 1.8–39.8). The maximal lenalidomide dose was 10 mg in 42 patients (98%), which was also the dose most commonly used during maintenance in 27 patients (63%), while 5 mg and 2.5 mg were used most commonly in 13 (30%) and 3 (7%) patients, respectively. Seven patients (16%) discontinued one maintenance drug (daratumumab, n=3; lenalidomide, n=4) during follow-up. The reasons for discontinuing daratumumab were insurance-related barriers, completion of planned duration and achieving MRD negativity (n=1 each). All four lenalidomide discontinuations were due to toxicity. At data cutoff, 37 patients (86%) remained on at least one maintenance drug, whereas 6 (14%) discontinued both drugs.

Complete response rates increased from 23% before autoHCT to 42% at day 100 and 60% as best post-autoHCT response. Corresponding rates of ≥very good partial response were 72%, 79%, and 86%, respectively.

Prior to autoHCT, 18 of 43 patients (42%) were MRD-negative. At day 100, 7 of 14 evaluable patients (50%) were MRD-negative. After maintenance initiation, 11 patients had at least one documented MRD assessment, the first assessment was obtained at a median of 280 days after maintenance initiation (range, 41–765). Among 6 patients with available pre- and post-maintenance MRD results, two converted from MRD-positive to MRD-negative, two remained MRD-positive, and two remained MRD-negative.

After a median follow-up of 12.1 months from autoHCT (range, 5.7–43.8), the estimated 1-year and 2-year PFS rates were 95% and 88%, respectively. Estimated 2-year OS was 100%.

Conclusion: In this real-world cohort, D-R maintenance following D-VRd induction and upfront autoHCT appeared feasible and was associated with deepening responses and encouraging early survival outcomes, despite approximately half of patients having high-risk disease. Most patients remained on at least one maintenance drug at data cutoff. MRD-positive-to-negative conversion was observed in a small subset with paired MRD assessments.

Khalid G. G. Alharbi, MBBS: No relevant conflicts of interest to declare.